Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition

Excerpt from the Press Release:

PEABODY, Mass., Aug. 19, 2021 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal cancers, announced today that Privo and its CEO, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition. Privo was selected from among 47 female-led oncology start-ups as the winner of the inaugural competition. AIM-HI has rewarded Privo with investments totaling $900,000; $300,000 from AIM-HI with matching investments from two supporters of the Women’s Venture Competition.

“The AIM-HI Women’s Venture Competition is making a real difference in funding research and innovative cancer treatments by women scientists – breakthrough cancer treatments,” said Dr. Goldberg, CEO. “I am honored to have been selected as the program’s inaugural winner and believe that AIM-HI and its investment in Privo Technologies will provide a critical endorsement of our technology and reassure others seeking to invest in new and innovative cancer therapies. This funding will support our preparation for two upcoming Phase 3 trials that will allow for New Drug Application submission, accelerating the timeline to get our lead asset into the clinic to start helping patients with significant unmet medical needs as soon as possible.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release